Trial intelligence / Profile preview

PK and Safety of SafeTynadol vs Panadol in Healthy Volunteers

NCT03451487Phase 1Completed

Sponsor
Sinew Pharma
Start
May 2022
Primary completion
Dec 2022
Modality
Orthosteric Ligands
Countries
1
01

Overview

Phase 1, randomised, single-blind trial of SNP-810 in pain and fever (6 arms), sponsored by Sinew Pharma. Primary endpoint: Percentage change from baseline of ALT peak level. Started May 2022; status: completed.

02

Drugs

SNP-810
03

Conditions

painfever

Beyond the preview

Go deeper on NCT03451487.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03451487.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call